Wrocław, 15th March 2021 – Captor Therapeutics S.A., a biopharmaceutical company developing drug candidates for the treatment of cancer and autoimmune diseases using innovative protein degradation technology, intends to conduct a public offering and apply for admission and introduction of the company’s shares to trading on the Warsaw Stock Exchange (Offering).
The full press release is available: here.
Dislaimer:
This announcement, or any part of it, is not intended for distribution, directly or indirectly, in the territory or to the United States of America, Canada, Japan, Australia or other countries where the public dissemination of the information contained in this announcement may be restricted or unlawful.
This announcement does not constitute an offer to sell or a solicitation to subscribe for or purchase the Company's securities in the United States of America, Australia, Canada, Japan or any other jurisdiction where to do so would violate applicable law or require registration. The securities referred to in this announcement may not be offered or sold in the United States of America, Canada, Japan or Australia without registration or exemption from registration. No public offering of the securities described in this announcement will be made in the United States of America, Canada, Japan or Australia.
This communication is an advertisement. The prospectus, after its approval by the Polish Financial Supervision Authority, will be the only legally binding offering document containing information about Captor Therapeutics S.A. with its registered office in Wrocław (the "Company"), the company's shares (including the offered shares) and the offer of the Company's shares. Subscriptions for the shares offered by the Company should be made only on the basis of the information contained in the prospectus, which will be published by the Company after its approval by the Polish Financial Supervision Authority. After approval by the Polish Financial Supervision Authority, the prospectus will be published and available on the Company's website: www.captortherapeutics.pl.
By approving the Prospectus, the Polish Financial Supervision Authority does not verify or approve the Company's business model, methods of conducting business activity and the method of its financing. In the proceedings for the approval of the Prospectus, neither the truthfulness of the information contained in the Prospectus nor the level of risk related to the Company's activities and the investment risk related to the purchase of the Company's securities are assessed. It is recommended that potential investors carefully read the content of the entire Prospectus, and in particular the risks related to investing in the Company's shares, included in the chapter "Risk factors" and the terms and conditions of the public offering. Any investment decisions regarding the Company's securities should be made only after considering the content of the entire Prospectus along with any supplements and updates to the Prospectus, as well as information on the final share price for individual categories of investors, the final number of shares offered under the Offering, as well as, possibly , about the final number and categories of shares offered to each category of investors (after their preparation and publication).
